TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting.
Animals
Antineoplastic Agents
/ pharmacology
Biomarkers
Humans
Molecular Targeted Therapy
Neoplasms
/ drug therapy
Proto-Oncogene Proteins
/ genetics
Receptor Protein-Tyrosine Kinases
/ genetics
Signal Transduction
T-Lymphocytes
/ immunology
Tumor Microenvironment
/ drug effects
c-Mer Tyrosine Kinase
/ genetics
Axl Receptor Tyrosine Kinase
CITIM 2019
Costimulation
MERTK
PROS1
T lymphocytes
TAM receptors
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
08
07
2019
accepted:
18
10
2019
pubmed:
31
10
2019
medline:
15
2
2020
entrez:
31
10
2019
Statut:
ppublish
Résumé
The TAM receptors-TYRO3, AXL, MERTK-are pleiotropically expressed receptors in both healthy and diseased tissue. A complex of the ligands Protein S (PROS1) or Growth Arrest-Specific 6 (GAS6) with apoptotic phosphatidylserine activates the TAM receptors. Hence, this receptor family is essential for the efferocytosis of apoptotic material by antigen-presenting cells. In addition, TAM receptors are expressed by virtually all cells of the tumor microenvironment. They are also potent oncogenes, frequently overexpressed in cancer and involved in survival and therapy resistance. Due to their pro-oncogenic and immune-inhibitory traits, TAM receptors have emerged as promising targets for cancer therapy. Recently, TAM receptors have been described to function as costimulatory molecules on human T cells. TAM receptors' ambivalent functions on many different cell types therefore make therapeutic targeting not straight-forward. In this review we summarize our current knowledge of the function of TAM receptors in the tumor microenvironment. We place particular focus on TAM receptors and the recently unraveled role of MERTK in activated T cells and potential consequences for anti-tumor immunity.
Identifiants
pubmed: 31664482
doi: 10.1007/s00262-019-02421-w
pii: 10.1007/s00262-019-02421-w
pmc: PMC7000491
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers
0
Proto-Oncogene Proteins
0
MERTK protein, human
EC 2.7.10.1
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
TYRO3 protein, human
EC 2.7.10.1
c-Mer Tyrosine Kinase
EC 2.7.10.1
Axl Receptor Tyrosine Kinase
0
AXL protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
237-244Subventions
Organisme : H2020 Marie Skłodowska-Curie Actions
ID : 641549
Organisme : H2020 Marie Skłodowska-Curie Actions
ID : 641549
Références
Neuron. 1991 May;6(5):691-704
pubmed: 2025425
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385715
Nature. 2014 Mar 27;507(7493):508-12
pubmed: 24553136
Nat Immunol. 2014 Oct;15(10):920-8
pubmed: 25194421
Arthritis Res Ther. 2014 Mar 21;16(2):R76
pubmed: 24650765
Cancer Res. 2019 Apr 15;79(8):1996-2008
pubmed: 30723115
Clin Cancer Res. 2017 Mar 15;23(6):1481-1492
pubmed: 27649555
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11484-9
pubmed: 9326636
Cancer Res. 2017 Jun 1;77(11):2775-2778
pubmed: 28526769
Immunol Rev. 2017 Mar;276(1):165-177
pubmed: 28258690
Cancers (Basel). 2016 Nov 08;8(11):
pubmed: 27834816
Cancers (Basel). 2016 Oct 21;8(10):
pubmed: 27775650
Mol Cancer. 2018 Jan 31;17(1):20
pubmed: 29386018
Science. 2001 Jul 13;293(5528):306-11
pubmed: 11452127
Blood. 2011 Feb 10;117(6):1928-37
pubmed: 21135257
Haematologica. 2007 May;92(5):643-50
pubmed: 17488688
PLoS One. 2014 Dec 16;9(12):e115140
pubmed: 25514676
Immunity. 2013 Jul 25;39(1):160-70
pubmed: 23850380
Blood. 2009 Mar 12;113(11):2470-7
pubmed: 18840707
Nat Commun. 2019 Apr 3;10(1):1515
pubmed: 30944303
PLoS One. 2013 Jun 20;8(6):e64812
pubmed: 23840307
J Immunol. 2008 Jun 1;180(11):7728-35
pubmed: 18490777
Oncoimmunology. 2017 Sep 14;7(1):e1364828
pubmed: 29296515
J Clin Invest. 2018 Jun 1;128(6):2356-2369
pubmed: 29708510
J Med Chem. 2016 Apr 28;59(8):3593-608
pubmed: 26555154
Annu Rev Immunol. 2015;33:355-91
pubmed: 25594431
Nat Immunol. 2006 Jul;7(7):747-54
pubmed: 16751775
Nat Rev Cancer. 2014 Dec;14(12):769-85
pubmed: 25568918
Science. 2016 Apr 1;352(6281):99-103
pubmed: 27034374
J Immunol. 2007 May 1;178(9):5635-42
pubmed: 17442946
Mol Cancer Res. 2017 Jun;15(6):753-764
pubmed: 28184013
Clin Cancer Res. 2006 May 1;12(9):2662-9
pubmed: 16675557
J Biol Chem. 2014 Sep 12;289(37):25750-63
pubmed: 25074926
J Autoimmun. 2014 Sep;53:78-84
pubmed: 24768065
J Thromb Haemost. 2018 Feb;16(2):352-363
pubmed: 29045015
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13091-6
pubmed: 23878224
Oncogene. 2006 Oct 5;25(45):6092-100
pubmed: 16652142
Immunity. 2019 May 21;50(5):1149-1162
pubmed: 31117011
Eur J Immunol. 2003 Aug;33(8):2160-7
pubmed: 12884290
Cell Death Differ. 2016 Jun;23(6):962-78
pubmed: 26915293
Cancer Immunol Res. 2019 Sep;7(9):1472-1484
pubmed: 31266785
Clin Cancer Res. 2015 May 1;21(9):2115-26
pubmed: 25673699
Nature. 1999 Apr 22;398(6729):723-8
pubmed: 10227296
Cell Immunol. 1997 Nov 1;181(2):120-6
pubmed: 9398399
J Thromb Haemost. 2010 Aug;8(8):1797-808
pubmed: 20546121
Mol Cell Neurosci. 2006 Sep;33(1):96-108
pubmed: 16901715
Mediators Inflamm. 2017;2017:6848430
pubmed: 28270700
J Thromb Haemost. 2005 Apr;3(4):733-41
pubmed: 15733062
J Leukoc Biol. 2015 Apr;97(4):751-60
pubmed: 25624460